Piper Sandler analyst David Westenberg lowered the firm’s price target on NeoGenomics (NEO) to $12 from $18 and keeps an Overweight rating on the shares. The firm updated the company’s model post the earnings report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics, Sherwin-Williams, Grab, Paccar, First Solar: Trending by Analysts
- NeoGenomics: Hold Rating Amid Mixed Performance and Uncertain MRD Pathway
- NeoGenomics price target lowered to $10 from $17 at Morgan Stanley
- NeoGenomics price target lowered to $12 from $17 at TD Cowen
- NeoGenomics price target lowered to $10 from $12 at BofA